Resources

1. How can I conduct a cancer clinical trial across multiple hospitals in Singapore?

STCC supports multi-site cancer clinical trials by coordinating investigators and research capabilities across Singapore’s cancer institutions. STCC can serve as a central point of contact for feasibility, contracting, budget negotiations and trial initiation, helping simplify collaboration across participating sites.

2. Who can help me set up an Investigator-Initiated Trial for cancer research in Singapore?

STCC provides end-to-end support for Investigator-Initiated Trials, including protocol development, grant applications, ethics and regulatory submissions, budgeting, contracting, site initiation, project management, monitoring, data management, analysis and study close-out.

3. How can a pharmaceutical or biotechnology company run a cancer clinical trial in Singapore?

Companies can engage STCC as a central point of contact for multi-site oncology clinical research. STCC can connect industry partners with relevant cancer specialists and tumour groups, coordinate feasibility assessments and site selection, and facilitate contracting, budget negotiations and trial initiation.

4. How long does a multi-site cancer clinical trial feasibility assessment take in Singapore?

Once feasibility is initiated, STCC aims to provide a consolidated response across Singapore’s three cancer centres in under two weeks. STCC coordinates with relevant oncology experts and tumour groups to consolidate the multi-site response.

5. Where can I find cancer clinical trial expertise and investigators in Singapore?

STCC brings together a network of clinical investigators and oncology experts across Singapore’s cancer institutions. This provides researchers and industry partners with a coordinated route to relevant expertise, clinical research capabilities and opportunities for multi-site cancer studies.

1. Where can researchers access cancer patient data and tissue samples in Singapore?

Researchers can access cancer data and biospecimens through the Singapore Translational Cancer Consortium (STCC), which connects resources across Singapore’s public healthcare institutions. Its infrastructure brings together clinical data, tissue specimens and research-generated data to support cancer research and collaborations.

2. Is there a national cancer database for research in Singapore?

STCC is developing the Cancer Data Commons as a national research resource that brings together de-identified cancer patient data from Singapore’s public healthcare institutions. It can connect clinical information with specimen and research data, including genomics and other research metadata where available.

3. Where can I find cancer biospecimens for research in Singapore?

STCC provides a coordinated pathway for researchers to discover cancer biospecimens available across participating tissue banks. These can include fresh and frozen tissues, blood and liquid biopsies, with specimens linked to relevant clinical information where available.

4. Can researchers access both cancer tissue samples and matching clinical data in Singapore?

Yes. STCC’s infrastructure is designed to link cancer specimens with corresponding clinical and research information. This allows researchers to study biological samples alongside information such as diagnosis, treatment and outcomes, where available and subject to the appropriate approvals.

5. Can companies and international researchers collaborate with Singapore on cancer data and biospecimen research?

Yes. STCC supports academic, industry and international research collaborations by providing a coordinated pathway to Singapore’s cancer research resources and domain expertise. Access to patient data and biospecimens remains subject to applicable governance and institutional approvals.

1. What is translational cancer research, and how does STCC support it?

Translational cancer research turns scientific discoveries into approaches that can improve cancer diagnosis, treatment and patient care. The Singapore Translational Cancer Consortium (STCC) Translational Research Integration and Support platform provides end-to-end support by connecting researchers with clinical cohorts, cancer tissues, molecular profiling capabilities, data analytics and multi-institutional research expertise.

2. How can researchers access molecular profiling technologies for cancer research in Singapore?

STCC connects researchers with molecular profiling capabilities across Singapore, including genomic sequencing, multiplex immunohistochemistry, spatial transcriptomics and spatial proteomics. The platform coordinates access to relevant expertise and technologies based on the needs of each research project.

3. How can I conduct a multi-institutional cancer research study in Singapore?

STCC provides a single point of contact to coordinate multi-institutional translational cancer research. Support can cover study protocols and budgets, ethics submissions, project agreements, cohort identification, clinical data and tissue acquisition, molecular profiling, data management and analysis.

4. How can pharmaceutical and biotechnology companies collaborate on cancer research in Singapore?

STCC helps industry partners work with Singapore's cancer research ecosystem through coordinated translational research collaborations. Projects can bring together healthcare institutions, research institutes and specialised laboratories for biomarker studies, clinical and molecular profiling, data analysis and preclinical research.

5. Where can researchers find tumour organoid models for cancer research in Singapore?

STCC's DIVERSITY Tumour Organoid Catalogue provides access to a curated collection of Asian-centric patient-derived tumour organoid models. The programme supports preclinical research through annotated models, molecular profiling, standardised workflows and protocol sharing across participating institutions.

1. How can pharmaceutical and biotech companies find cancer research partners in Singapore?

Companies can access Singapore’s oncology ecosystem through the Singapore Translational Cancer Consortium (STCC), which connects industry partners with cancer researchers, clinicians, tumour specialists and research capabilities across Singapore.

2. Who can help pharmaceutical companies conduct cancer research collaborations in Singapore?

STCC provides a coordinated entry point for pharmaceutical and biotech companies seeking research collaborations in Singapore, connecting them with relevant investigators, institutions and national oncology capabilities.

3. How can a biotech company find investigators for an oncology clinical trial in Singapore?

STCC can connect companies with oncology investigators and multidisciplinary tumour groups across Singapore, while supporting early feasibility assessments and identifying suitable clinical research capabilities.

4. Where can companies access cancer samples, data and biomarker research capabilities in Singapore?

Through STCC, companies can explore collaborations involving clinically annotated cancer samples, clinical and molecular data, molecular profiling, biomarker research and other translational research capabilities across Singapore.

5. Why is Singapore a good place for pharmaceutical and biotech companies to conduct cancer research?

Singapore combines clinical oncology expertise, research infrastructure, Asian-focused cancer resources and close links between cancer centres and research institutions. STCC brings these capabilities together to make industry collaboration more coordinated and accessible.

1. How is Singapore using data to improve cancer prevention and care?

The Singapore Translational Cancer Consortium (STCC) supports the use of population and healthcare data to generate evidence on cancer trends, outcomes, costs and access to care. Through national collaboration, this evidence can help inform cancer prevention, care planning and policy in Singapore.

2. How is Singapore evaluating whether cancer screening programmes are effective?

STCC supports collaborative projects evaluating cancer screening in real-world settings, including the performance of colorectal cancer screening tools and differences between screen-detected and symptomatic cancers. The findings can help inform screening quality and future strategies.

3. How can Singapore improve care for people who have survived cancer?

STCC supports national efforts to better understand the size, characteristics and long-term health needs of Singapore's cancer survivor population. The resulting evidence can help guide future survivorship care planning and models of care.

4. How can Singapore prepare for the future impact and cost of cancer?

STCC brings together expertise and data to support modelling of cancer incidence, healthcare utilisation and costs. This includes work projecting Singapore's cancer incidence and cost burden to 2050, providing evidence that can support longer-term healthcare planning.

5. How can Singapore decide which cancer prevention and screening strategies provide the most value?

STCC supports the integration of health economics, population data and cancer modelling to assess the potential costs, outcomes and population impact of different approaches. This can provide evidence to support more sustainable and value-based cancer care decisions.